Kallinowski, Birgit and Jilg, W. and Buchholz, L. and Stremmel, W. and Engler, S. (2003) Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 41 (10). pp. 983-990. ISSN 0044-2771
Full text not available from this repository. (Request a copy)Abstract
Objectives: Hepatitis A (HAV) and B (HBV) vaccinations are recommended in patients with chronic liver diseases. Methods: We prospectively investigated immunogenicity and safety of an accelerated vaccination protocol (0-7-21 days) with the combined hepatitis A/B vaccine (Twinrix(R)) versus the standard vaccination scheme (0-1-6 months) in hepatitis C virus-infected patients versus healthy volunteers. Results: Local and general symptoms were mostly mild in all groups. One month after completion of the accelerated vaccination or standard vaccination, with the combined hepatitis A/B vaccine anti-HAV seroconversion rates (>33 IU/l) were 89% and 88% in HCV-infected patients. Initial HCV-nonresponders developed protective anti-HAV antibodies in 94% and 96% after a booster dose. According to the anti-HBs seroprotection rate, HCV-infected patients developed protective anti-HBs titres (>10 IU/l) in 77 % and 82 % of cases one month after the accelerated and the standard vaccination scheme-at month 2 and 7, respectively. This anti-HBs seroprotection rate could even be increased to 84% and 85 % when initial HCV-infected nonresponders where given a booster dose with the combined hepatitis A/B vaccine. Protective anti-HAV and anti-HBs titers were achieved as early as month 2 after the accelerated vaccination schedule in the majority of HCV-infected patients. Healthy subjects developed protective anti-HAV titers and anti-HBs titers in 100% and 98 % after the accelerated and standard vaccination protocol. Conclusions: This study is the first to have demonstrated that the accelerated combined hepatitis A/B vaccination is both safe and highly immunogenic against HAV and HBV in HCV-infected patients with well compensated liver disease.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CHRONIC LIVER-DISEASE; CORRESPONDING MONOVALENT VACCINES; B VACCINE; A VACCINE; TRANSPLANT RECIPIENTS; VIRUS SUPERINFECTION; SAFETY; INDIVIDUALS; SCHEDULE; hepatitis A/B vaccine; hepatitis C virus infection; accelerated vaccination |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Aug 2021 09:53 |
| Last Modified: | 30 Aug 2021 09:53 |
| URI: | https://pred.uni-regensburg.de/id/eprint/38589 |
Actions (login required)
 |
View Item |
